Floatz logo

ly4052031

Renal Pelvis Cancer

Eli Lilly and CompanyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Renal Pelvis Cancer cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
H. Lee Moffitt Cancer Center and Research Institute
Phase 3BB
Vinflunine
Dr Anders Ullén
Phase 2BB
Pembrolizumab
Alliance for Clinical Trials in Oncology
Phase 3B
Icrucumab
Eli Lilly and Company
Phase 2B
IMMUNOGLOBULIN G1, ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYPE VEGFR-2 EXTRACELLULAR DOMAIN) (HUMAN MONOCLONAL IMC-1121B .GAMMA.-CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL IMC-1121B .KAPPA.-CHAIN, DIMER
Eli Lilly and Company
Phase 2B

View all 17 →

Same molecule, other indications

ly4052031 is also rated in:

cancerDormant
CC
Indicative ·
43 / 100
View asset →
urinary bladder neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
urinary bladder carcinomaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →